Prestige Consumer Healthcare (NYSE:PBH) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of Prestige Consumer Healthcare (NYSE:PBH) from a hold rating to a buy rating in a research report report published on Tuesday morning.

Several other equities research analysts have also recently weighed in on PBH. Oppenheimer upped their price target on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research note on Thursday, February 13th. Canaccord Genuity Group upped their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a research note on Monday, December 9th. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Finally, DA Davidson increased their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of “Moderate Buy” and a consensus target price of $92.60.

Prestige Consumer Healthcare Price Performance

PBH opened at $84.22 on Tuesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68. Prestige Consumer Healthcare has a 52-week low of $62.35 and a 52-week high of $90.04. The stock has a market capitalization of $4.17 billion, a PE ratio of 19.72, a price-to-earnings-growth ratio of 2.69 and a beta of 0.46. The stock’s 50 day moving average price is $82.25 and its 200-day moving average price is $78.53.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. On average, equities research analysts predict that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

Insider Activity

In other news, SVP Mary Beth Fritz sold 1,678 shares of the company’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the transaction, the senior vice president now directly owns 17,157 shares of the company’s stock, valued at $1,544,130. This represents a 8.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Kestra Investment Management LLC bought a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at $27,000. CIBC Private Wealth Group LLC lifted its holdings in shares of Prestige Consumer Healthcare by 48.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock valued at $34,000 after purchasing an additional 152 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at $40,000. Huntington National Bank lifted its holdings in shares of Prestige Consumer Healthcare by 39.9% during the third quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after purchasing an additional 181 shares in the last quarter. Finally, McIlrath & Eck LLC lifted its holdings in Prestige Consumer Healthcare by 19.1% in the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company’s stock valued at $75,000 after acquiring an additional 154 shares during the period. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.